Profile data is unavailable for this security.
About the company
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
- Revenue in USD (TTM)94.86m
- Net income in USD-23.99m
- Incorporated1997
- Employees209.00
- LocationNeuropace Inc455 N. Bernardo AvenueMOUNTAIN VIEW 94043United StatesUSA
- Phone+1 (650) 237-2700
- Fax+1 (650) 237-2701
- Websitehttps://www.neuropace.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clearpoint Neuro Inc | 34.33m | -23.14m | 403.09m | 115.00 | -- | 24.27 | -- | 11.74 | -0.8264 | -0.8264 | 1.23 | 0.5584 | 0.6829 | 1.95 | 7.52 | 298,539.10 | -46.03 | -35.94 | -54.48 | -41.48 | 61.31 | 63.49 | -67.40 | -74.87 | 5.56 | -92.37 | 0.6479 | -- | 31.04 | 22.85 | 14.37 | -- | 11.41 | -- |
| Myriad Genetics Inc | 825.30m | -400.50m | 418.53m | 2.70k | -- | 1.12 | -- | 0.5071 | -4.34 | -4.34 | 8.97 | 4.00 | 0.9122 | 8.46 | 6.77 | 305,666.70 | -44.27 | -- | -53.15 | -- | 70.36 | -- | -48.53 | -- | 2.12 | -14.93 | 0.2427 | -- | 11.21 | -- | 51.65 | -- | -- | -- |
| Orthopediatrics Corp | 227.41m | -45.61m | 423.56m | 562.00 | -- | 1.21 | -- | 1.86 | -1.96 | -1.96 | 9.74 | 13.93 | 0.4628 | 0.5149 | 4.83 | 404,644.10 | -9.28 | -5.87 | -9.97 | -6.44 | 71.73 | 74.27 | -20.06 | -16.55 | 3.52 | -5.96 | 0.2214 | -- | 37.65 | 23.06 | -80.33 | -- | 4.29 | -- |
| Cerus Corp | 225.97m | -15.96m | 430.28m | 281.00 | -- | 7.00 | -- | 1.90 | -0.0848 | -0.0848 | 1.20 | 0.3201 | 1.12 | 1.99 | 8.35 | 804,163.70 | -7.91 | -20.38 | -12.30 | -31.96 | 60.50 | 61.15 | -7.09 | -25.37 | 1.29 | -1.04 | 0.5772 | -- | 7.78 | 16.51 | 44.20 | -- | -20.50 | -- |
| Standard Biotools Inc | 128.83m | -109.46m | 430.71m | 818.00 | -- | 1.08 | -- | 3.34 | -0.289 | -0.3383 | 0.3399 | 1.04 | 0.211 | 1.97 | 5.27 | 157,490.20 | -17.93 | -29.45 | -22.06 | -35.68 | 47.94 | 50.11 | -84.97 | -79.68 | 4.14 | -- | 0.0008 | -- | 64.03 | 8.27 | -147.67 | -- | 26.98 | -- |
| AngioDynamics, Inc. | 307.31m | -27.71m | 452.15m | 675.00 | -- | 2.59 | -- | 1.47 | -0.6731 | -0.6731 | 7.47 | 4.24 | 1.10 | 2.12 | 7.02 | 455,268.20 | -9.87 | -13.69 | -13.83 | -16.19 | 54.58 | 52.46 | -9.02 | -21.32 | 1.33 | -- | 0.0329 | -- | -3.76 | 2.06 | 81.56 | -- | -10.06 | -- |
| Neuropace Inc | 94.86m | -23.99m | 497.88m | 209.00 | -- | 27.05 | -- | 5.25 | -0.7535 | -0.7535 | 2.98 | 0.5564 | 0.9321 | 1.46 | 7.16 | 515,565.20 | -23.57 | -35.71 | -28.36 | -44.34 | 76.77 | 73.39 | -25.28 | -60.45 | 3.94 | -3.58 | 0.7603 | -- | 22.14 | 16.67 | 17.64 | -- | -8.15 | -- |
| Mesa Laboratories Inc | 247.54m | 3.73m | 500.49m | 730.00 | 140.00 | 2.68 | 17.41 | 2.02 | 0.6471 | 0.6471 | 44.81 | 33.79 | 0.5678 | 3.40 | 6.28 | 339,097.30 | 0.8564 | -8.81 | 1.13 | -9.71 | 62.40 | 61.98 | 1.51 | -25.15 | 1.45 | 1.62 | 0.4709 | -- | 11.47 | 15.41 | 99.22 | -- | 24.60 | 0.00 |
| Pacific Biosciences of California Inc | 160.01m | -546.38m | 516.26m | 575.00 | -- | 96.52 | -- | 3.23 | -1.84 | -1.84 | 0.5335 | 0.0177 | 0.1565 | 1.96 | 5.08 | -- | -53.45 | -22.47 | -59.23 | -24.40 | 33.97 | 33.11 | -341.47 | -214.45 | 2.44 | -19.72 | 0.9918 | -- | 3.89 | 15.19 | -76.34 | -- | -- | -- |
| Anteris Technologies Global Corp | 2.14m | -84.32m | 523.69m | 136.00 | -- | 55.68 | -- | 244.82 | -2.34 | -2.34 | 0.0594 | 0.1025 | 0.1065 | 1.53 | 11.88 | 15,728.75 | -420.16 | -- | -1,527.00 | -- | 67.94 | -- | -3,945.70 | -- | 0.8032 | -- | 0.046 | -- | -1.16 | -- | -65.77 | -- | -- | -- |
| Orthofix Medical Inc | 818.06m | -119.12m | 529.84m | 1.62k | -- | 1.19 | -- | 0.6477 | -3.04 | -3.04 | 20.82 | 11.20 | 0.9622 | 1.37 | 6.40 | 506,224.00 | -14.01 | -10.81 | -17.28 | -13.34 | 68.27 | 70.31 | -14.56 | -11.57 | 1.38 | -1.35 | 0.2837 | -- | 7.08 | 11.69 | 16.78 | -- | 8.75 | -- |
| Cytek Biosciences Inc | 196.83m | -12.82m | 542.15m | 692.00 | -- | 1.43 | -- | 2.75 | -0.1011 | -0.1011 | 1.54 | 2.96 | 0.3992 | 1.86 | 3.60 | 303,746.90 | -2.60 | 0.3407 | -3.02 | 0.3811 | 53.46 | 58.12 | -6.51 | 0.8678 | 4.48 | -- | 0.0213 | -- | 3.85 | 28.20 | 50.44 | -- | 30.83 | -- |
| Varex Imaging Corp | 854.40m | -67.70m | 566.49m | 2.40k | -- | 1.19 | -- | 0.663 | -1.63 | -1.63 | 19.34 | 11.38 | 0.7032 | 1.85 | 6.00 | 356,000.00 | -5.55 | -0.3327 | -6.45 | -0.3955 | 34.15 | 33.16 | -7.89 | -0.4661 | 1.87 | 2.22 | 0.4321 | -- | 4.14 | 2.73 | -47.38 | -- | -0.5159 | -- |
| Tactile Systems Technology Inc | 311.51m | 18.17m | 590.78m | 1.04k | 34.05 | 2.88 | 23.72 | 1.90 | 0.7768 | 0.7768 | 13.28 | 9.18 | 1.14 | 8.38 | 8.07 | 300,398.30 | 6.64 | 1.29 | 7.72 | 1.55 | 49.87 | 49.12 | 5.83 | 1.26 | 3.20 | -- | 0.00 | 0.00 | 6.76 | 9.11 | -40.52 | 9.10 | -15.97 | -- |
Data as of Feb 13 2026. Currency figures normalised to Neuropace Inc's reporting currency: US Dollar USD
50.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Polar Capital LLPas of 30 Sep 2025 | 3.10m | 9.30% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 2.70m | 8.12% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.54m | 7.63% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.69m | 5.07% |
| First Light Asset Management LLCas of 30 Sep 2025 | 1.36m | 4.08% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.30m | 3.90% |
| Armistice Capital LLCas of 30 Sep 2025 | 1.30m | 3.90% |
| Kent Lake PR LLCas of 30 Sep 2025 | 1.00m | 3.00% |
| Driehaus Capital Management LLCas of 30 Sep 2025 | 939.52k | 2.82% |
| DWS Investments (UK) Ltd.as of 31 Dec 2025 | 929.15k | 2.79% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
